Varda Space Industries raised $251 million in a Series D round to advance pharmaceutical manufacturing in space. The company positions microgravity as a platform for producing drug substances that can be harder to make—or produce at lower defect rates—on Earth. The financing signals continued investor appetite for “space pharma” as an enabling technology rather than a single-product bet, with the capital intended to support manufacturing capabilities and scaling of the platform. For biotech decision-makers, the key question is whether space-manufactured outputs can translate into clear downstream advantages for formulation stability, product consistency, or reduced CMC risk. The round also strengthens the competitive landscape among nontraditional manufacturing models that seek regulatory and commercial acceptance.